<DOC>
	<DOCNO>NCT01327846</DOCNO>
	<brief_summary>Main Study ( CACZ885M2301 ) : The purpose pivotal phase trial test hypothesis canakinumab treatment patient MI least one month prior study entry elevate hsCRP prevent recurrent cardiovascular event . The purpose extension phase main study collect additional long-term safety data continue exposure canakinumab patient participate pivotal phase . Sub-study 1 ( CACZ885M2301S1 ) : The purpose sub-study evaluate effect quarterly subcutaneous canakinumab treatment 24 month compart placebo carotid plaque burden measure integrated vascular MRI patient enrol CACZ885M2301 study ( CANTOS ) . Sub-study 2 ( CACZ885M2301S2 ) : The purpose CANTOS sub-study determine whether , patient type 2 diabetes participate CANTOS main study , canakinumab compare placebo , top standard care increase insulin secretion insulin sensitivity .</brief_summary>
	<brief_title>Cardiovascular Risk Reduction Study ( Reduction Recurrent Major CV Disease Events )</brief_title>
	<detailed_description>There seamless transition pivotal phase extension phase main study . LPLV pivotal phase 02/2017 .</detailed_description>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Main Study Written inform consent Male , Female nonchildbearing potential Age ≥ 18 year . Spontaneous MI least 30 day randomization . hsCRP ≥ 2 mg/L Substudy 1 Inclusion : All Inclusion Main Study Acquisition evaluable baseline MRI image bilateral carotid artery image core laboratory Substudy 2 Inclusion : All inclusion Main Study T2D baseline per Main protocol criterion stable antihyperglycemic medication least 4 week prior baseline OGTT test Willing OGTT assessment start 10 Main Study Pregnant nursing ( lactate ) woman Women childbearing potential Any follow concomitant disease Planned coronary revascularization ( PCI CABG ) Major noncardiac surgical endoscopic procedure within past 6 month Multivessel CABG surgery within past 3 year Symptomatic patient Class IV heart failure ( HF ) ( New York Heart Association [ NYHA ] . Uncontrolled hypertension Uncontrolled diabetes History evidence active tuberculosis ( TB ) infection Substudy 1 Exclusion All Main exclusion Patients prior history carotid angioplasty , stenting , carotid atherectomy Patients contraindication MRI examination ( brain aneurysm clip , implanted neural stimulator , implanted cardiac pacemaker , pacemaker wire defibrillator , prosthetic heart valve , cochlear implant , ocular foreign body implant body , tattoo , implanted insulin pump , metal shrapnel bullet ) Patients prone claustrophobia know anxiety disorder BMI &gt; 40 kg/m2 Substudy 2 Exclusion This substudy additional exclusion criterion . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cardiovascular Death</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Stroke</keyword>
	<keyword>Canakinumab</keyword>
	<keyword>IL-1B</keyword>
	<keyword>hsCRP</keyword>
</DOC>